Dr. Jason Mock is an intellectual property attorney that helps organizations of all sizes in every facet of the patent life cycle. Whether a client is developing and obtaining new patent rights, managing a complex portfolio, performing due diligence for a transaction, or enforcing or defending its rights, Jason has the experience to guide his clients and serve as a trusted advisor.
Jason’s practice spans industries including pharmaceuticals, diagnostics, biotechnology, synthetic biology and biomanufacturing, food science, and agriculture. He has a depth of knowledge to help his clients keep pace in changing environments and realize value from their IP. Jason’s clients range from startups and universities to multinational corporations. He is a member of the firm’s Chemical, Biotechnology, & Pharmaceutical Practice and the PTAB Trials Practice.
Presentations and Publications
- J. Mock, T. Yan, and K. Sharon, “IPR proactive defense measures – strategies and considerations for patent owners,” PTAB Trial Insights (May 2016)
- J. Mock, “Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions,” PTAB Trial Insights (January 2016)
- Author, “Post-Grant Proceedings at the USPTO and the Rising Tide of Federal Circuit Appeals,” The Federal Circuit Bar Journal (September 2015)
- Co-author, “The Road Ahead for Kyle Bass’s IPRs,” Law360 (August 2015)
- Co-author, “Will New PTAB Rules Impact IPRs Filed by Kyle Bass Hedge Fund?” The National Law Review (August 2015)
- Co-author, 鈥淪urvey of State Laws Against Bad-Faith Patent Assertion,鈥 Bloomberg BNA Patent, Trademark & Copyright Journal (August 2014)
- Co-author, 鈥淩ole of the Phospholipase A2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells,鈥 Mol. Pharmaceuticals (2014)
- Co-author, 鈥淓vidence for Distinct Mechanisms of Uptake and Antitumor Activity of Secretory Phospholipase A2 Responsive Liposomes in Prostate Cancer,鈥 Integr. Biol. (2012)
- Co-author, 鈥淗aloenol Pyranones and Morpholinones as Antineoplastic Agents of Prostate Cancer,鈥 Bioorg. and Med. Chem. Letters (2012)
- Co-author, 鈥淪ecretory Phospholipase A2 Responsive Liposomes,鈥 J. Pharm. Sci. (2011)
- Co-author, Enhanced Antitumor Activity of Low-Dose Continuous Administration Schedules of Topotecan in Prostate Cancer,鈥 Cancer Bio. and Therapy (2011)
麻豆传媒 Announces 23 New Partners
The BioPharma Patent Cliff: 2023 and Beyond
Health Care & Life Sciences Sector Top Trends for 2023
PTAB鈥檚 Motion to Amend Pilot Program: Review of Initial Results
COVID-19: Patent Procurement and Licensing
